Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study
Xiao Fu, Paul A. Bates(The Francis Crick Institute), Steve Hazell(Royal Marsden NHS Foundation Trust), Ben Challacombe(Guy's and St Thomas' NHS Foundation Trust), Nicos Fotiadis(Royal Marsden NHS Foundation Trust), Lavinia Spain(Royal Marsden NHS Foundation Trust), Sergio A. Quezada(Memorial Sloan Kettering Cancer Center), Kevin Litchfield(Cancer Research UK), Charles Swanton(The Francis Crick Institute), Matthew Orton(Royal Marsden NHS Foundation Trust), Peter Hill, Lisa Pickering(Royal Marsden Hospital), Mary Varia(Guy's and St Thomas' NHS Foundation Trust), Annika Fendler(The Francis Crick Institute), Jonathon Olsburgh(University of Basel), Emine Hatipoglu(Royal Marsden NHS Foundation Trust), Gordon Stamp(Royal Marsden Hospital), Simon Doran(Institute of Cancer Research), Dow‐Mu Koh(Royal Marsden NHS Foundation Trust), Catherine Horsfield(St Thomas' Hospital), Marcellus Augustine(The Francis Crick Institute), Samra Turajlic(Royal Marsden NHS Foundation Trust), José I. López(BioCruces Health research Institute), Christina Messiou(Institute of Cancer Research), Karen Harrison‐Phipps, Andrew Rowan(Cancer Institute (WIA)), Alexander Polson(Guy's and St Thomas' NHS Foundation Trust), Antonia Toncheva(Cancer Research UK), Fiona Byrne(The Francis Crick Institute), Ashish Chandra(Guy's Hospital), Lewis Au(Royal Marsden NHS Foundation Trust), James Larkin(Trinity College Dublin), Erik Sahai(The Francis Crick Institute), Scott T.C. Shepherd(Royal Marsden NHS Foundation Trust), Charlotte Spencer(The Francis Crick Institute), Derfel ap Dafydd(Royal Marsden Hospital), Yue Zhao(Jackson Laboratory), Hang Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Santosh Kumar(Institute of Cancer Research), David Nicol(Royal Stoke University Hospital), William Drake, Sarah Rudman(Guy's and St Thomas' NHS Foundation Trust), Hema Verma, Archana Fernando(Guy's and St Thomas' NHS Foundation Trust), Andrew Furness(Royal Marsden NHS Foundation Trust), Simon Chowdhury(Sarah Cannon Research Institute), Stuart Horswell(The Francis Crick Institute), Tim O’Brien(St Thomas' Hospital), Teresa Marafioti(Cancer Research UK)
Cited by 76
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
A framework for advancing our understanding of cancer-associated fibroblasts
|Nature reviews. Cancer|2020|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k